These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22106974)

  • 21. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia.
    Milicevic Z; Raz I; Beattie SD; Campaigne BN; Sarwat S; Gromniak E; Kowalska I; Galic E; Tan M; Hanefeld M
    Diabetes Care; 2008 Feb; 31 Suppl 2():S155-60. PubMed ID: 18227478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycemic control and cardiovascular mortality.
    Riddle MC
    Curr Opin Endocrinol Diabetes Obes; 2011 Apr; 18(2):104-9. PubMed ID: 21522000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Management of diabetes in cardiac diseases].
    Işik S; Delibaşi T; Berker D; Aydin Y; Güler S
    Anadolu Kardiyol Derg; 2009 Jun; 9(3):238-47. PubMed ID: 19520659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The association between erectile dysfunction and cardiovascular risk in men with Type 2 diabetes in primary care: it is a matter of age.
    Cleveringa FG; Meulenberg MG; Gorter KJ; van den Donk M; Rutten GE
    J Diabetes Complications; 2009; 23(3):153-9. PubMed ID: 18413203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glycemic control and complications in type 2 diabetes mellitus.
    Stolar M
    Am J Med; 2010 Mar; 123(3 Suppl):S3-11. PubMed ID: 20206730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving macrovascular outcomes in type 2 diabetes: Outcome studies in cardiovascular risk and metabolic control.
    Schneider CA
    Curr Med Res Opin; 2006; 22 Suppl 2():S15-26. PubMed ID: 16914072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dysglycaemia, cardiovascular outcome and treatment. Is the jury still out?
    Bartnik M; Cosentino F
    Eur Heart J; 2009 Jun; 30(11):1301-4. PubMed ID: 19395498
    [No Abstract]   [Full Text] [Related]  

  • 29. Cardiovascular risk factors in type 2 diabetes: the role of hyperglycaemia.
    Massi-Benedetti M; Federici MO
    Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S120-3. PubMed ID: 10522835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperlipidemia and cardiovascular risk factors in patients with type 2 diabetes.
    Goldberg RB
    Am J Manag Care; 2000 Aug; 6(13 Suppl):S682-91; discussion S692-6. PubMed ID: 11183421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
    Ovalle F
    Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular risk in the spectrum of type 2 diabetes mellitus.
    Ahmed I; Goldstein BJ
    Mt Sinai J Med; 2006 Sep; 73(5):759-68. PubMed ID: 17008936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid disorders in type 2 diabetes.
    Braun LT
    Nurs Clin North Am; 2001 Jun; 36(2):291-302, vii. PubMed ID: 11382564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eye complications and markers of morbidity and mortality in long-term type 1 diabetes.
    Grauslund J
    Acta Ophthalmol; 2011 Feb; 89 Thesis 1():1-19. PubMed ID: 21443578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus.
    Delorme S; Chiasson JL
    Curr Opin Pharmacol; 2005 Apr; 5(2):184-9. PubMed ID: 15780829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The diabetic, hypertensive heart: epidemiology and mechanisms of a very high-risk situation.
    Franjic B; Marwick TH
    J Hum Hypertens; 2009 Nov; 23(11):709-17. PubMed ID: 19516273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma homocysteine and microvascular and macrovascular complications in type 1 diabetes: a cross-sectional nested case-control study.
    Soedamah-Muthu SS; Chaturvedi N; Teerlink T; Idzior-Walus B; Fuller JH; Stehouwer CD;
    J Intern Med; 2005 Nov; 258(5):450-9. PubMed ID: 16238681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impaired glucose tolerance, impaired fasting glycaemia and cardiovascular risk.
    Sanusi H
    Acta Med Indones; 2004; 36(1):36-41. PubMed ID: 15673935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Common causes of admission in diabetics.
    Akbar DH; Al-Gamdi AA
    Saudi Med J; 2000 Jun; 21(6):539-42. PubMed ID: 11500701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetic dyslipidemia or 'diabetes lipidus'?
    Muačević-Katanec D; Reiner Z
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):341-8. PubMed ID: 21438813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.